Ocular Therapeutix's total inventories for the quarter that ended in Mar. 2026 was €3.23 Mil. Ocular Therapeutix's average total inventories from the quarter that ended in Dec. 2025 to the quarter that ended in Mar. 2026 was €3.14 Mil.
In Ben Graham's calculation of Net-Net Working Capital, inventory is only considered worth half of its book value. Ocular Therapeutix's Net-Net Working Capital per share for the quarter that ended in Mar. 2026 was €2.12.
Days Inventory indicates the number of days of goods in sales that a company has in the inventory.
Ocular Therapeutix's Days Inventory for the
three
months ended in Mar. 2026 was 249.03.
Inventory Turnover measures how fast the company turns over its inventory within a year.
Ocular Therapeutix's Inventory Turnover for the quarter that ended in Mar. 2026 was 0.37.
Inventory-to-Revenue determines the ability of a company to manage their inventory levels. It measures the percentage of Inventories the company currently has on hand to support the current amount of Revenue.
Ocular Therapeutix's Inventory-to-Revenue for the quarter that ended in Mar. 2026 was 0.34.
Ocular Therapeutix (FRA:0OT) Total Inventories Explanation
Inventory control is an important part of business operation. If a company does not have enough inventory, it may not be able to meet customers' required delivery time. If it has too much inventory, the cost of holding the inventory can be high.
1. In Ben Graham's calculation of Net-Net Working Capital (NNWC), inventory is only considered worth half of its book value.
Ocular Therapeutix's Net-Net Working Capital Per Share for the quarter that ended in Mar. 2026 is
4. Inventory-to-Revenue determines the ability of a company to manage their inventory levels. It measures the percentage of Inventories the company currently has on hand to support the current amount of Revenue.
Ocular Therapeutix's Inventory to Revenue for the quarter that ended in Mar. 2026 is calculated as
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Be Aware
Manufacturers with durable competitive advantages have the advantage that the products they sell do not change, and therefore will never become obsolete. Buffett likes this advantage.
When identifying manufacturers with durable competitive advantage, look for inventory and net earnings that rise correspondingly. This indicates that the company is finding profitable ways to increase sales which called for an increase in inventory.
Manufacturers with inventories that spike up and down are indicative of competitive industries subject to boom and bust.
Ocular Therapeutix Total Inventories Related Terms
Ocular Therapeutix Total Inventories Historical Data
* Premium members only.
The historical data trend for Ocular Therapeutix's Total Inventories can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Total Inventories includes the raw materials, work-in-process goods and completely finished goods of a company. It is a portion of a company's current assets.
Ocular Therapeutix (FRA:0OT) has a Total Inventories of €3.23 Mil as of Mar. 2026. The total amount of inventory as recorded on a company's balance sheet. View historical data for Ocular Therapeutix and its competitors.
Is Ocular Therapeutix's Total Inventories too high?
Ocular Therapeutix's current Total Inventories is €3.23 Mil. Overall, Ocular Therapeutix has a GF Score™ of 51/100 and is considered Significantly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Ocular Therapeutix's Total Inventories compare to AUPH and NTLA?
Ocular Therapeutix's Total Inventories of €3.23 Mil can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Total Inventories for a Biotechnology company?
A good Total Inventories depends on the Biotechnology industry context. However, Total Inventories should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Total Inventories mean?
A high Total Inventories can signal that a stock is expensive relative to its fundamentals. The total amount of inventory as recorded on a company's balance sheet. View historical data for Ocular Therapeutix and its competitors. Ocular Therapeutix's current Total Inventories is €3.23 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Ocular Therapeutix stock overvalued right now?
Based on GuruFocus' analysis, Ocular Therapeutix (FRA:0OT) is currently considered Significantly Overvalued. The stock's GF Value™ is €3.89, compared to a current price of €8.60 — trading 121.1% above its estimated fair value. The current Total Inventories is €3.23 Mil. Ocular Therapeutix's overall GF Score™ is 51/100 with 3 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Total Inventories calculated?
Total Inventories is calculated from a company's financial statements. For Ocular Therapeutix (FRA:0OT), the current Total Inventories is €3.23 Mil as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Ocular Therapeutix (FRA:0OT) Overvalued in 2026?
Based on GuruFocus' analysis, Ocular Therapeutix stock appears to be overvalued.
The current stock price of €8.60 is trading 121.1% above its estimated GF Value™ of €3.89.
GuruFocus considers Ocular Therapeutix to be Significantly Overvalued.
Key valuation signals for FRA:0OT:
Total Inventories: €3.23 Mil
GF Value™: €3.89 vs. price of €8.60 (121.1% above fair value)
No single metric tells the full story. See the FRA:0OT stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Ocular Therapeutix Inc is a biotechnology company that specializes in therapies for diseases and conditions of the eye. The company uses its proprietary hydrogel platform technology to deliver therapeutic agents to the eye. Its pipeline consists of eye medication that aims to overcome the limitations of current eye-drop-based therapies for ophthalmic diseases and conditions. Its pipeline product includes Dextenza, OTX-TIC, OTX-TKI, and OTX-IVT.
51GF Score
Get the complete analysis for FRA:0OT
Total Inventories is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
FRA:0OT has been successfully added to your 
